Early Access Programs

Closing the therapeutic gap – true to our core claim, we offer Early Access Programs and Expanded Access Programs (EAPs) for pharmaceutical companies.

Closing the therapeutic gap

Enabling access to medicines together.

Early Access Programs give patients access to medicines that have already been approved in one country but not (yet) in the patient's country. In addition, this enables those patients who can no longer be enrolled in a trial to find a therapy.
Within the framework of these hardship programs, ilapo wants to help close gaps in the supply of medicines and give every patient the opportunity to receive a therapy.

Prerequisites for the patient:

The products are used exclusively in therapy.
There is no approved alternative for the patient.
The patient's disease is significant.
Enrolment in a trial is not possible.

Medication requirements:

The product is already approved in a first country.
The product is not yet approved, but is being tested in a promising clinical trial.

If all the requirements are met, ilapo is happy to be your reliable partner in the Early Access Program.
We can ensure continued supply for your patients after the clinical trial has been completed until your new product is approved. In addition, we ensure customer loyalty and support you with marketing your new product.
Once your product has been approved in a first country, our Early Access Program enables you to start commercialisation in important key markets.